Forgot Password?
Return to Course Listing

CME: Recurrent and metastatic endometrial cancer: Therapeutic updates and optimizing treatment


Activity Description / Statement of Need:

In this online, self-learning activity:

Endometrial cancer, a type of cancer that originates in the lining of the uterus, is the most common gynecologic cancer and the fourth most common cancer in women living in the United States. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and the most common risk factors are obesity, diabetes, hypertension, and increasing age. Levels of the two hormone estrogen and progesterone fluctuate during the menstrual cycle, resulting in cell proliferation and differentiation that may lead to abnormalities that contribute to malignancies later in life. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis.

Target Audience:

The following HCPs: medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with recurrent or advanced endometrial cancer.

Commercial Support Disclosure: This program is supported by educational grants from Karyopharm.

This activity is free of charge.

Release Date: April 01, 2020 -- Expiration Date: April 01, 2022

Faculty: Daphne Stewart, MD


Faculty introduction, disclosures

Introduction content: Cursory refresher and review of endometrial cancer

  • Epidemiology: Statistics of endometrial cancer and survival by severity
  • Causes and risk factors for
  • Pathogenesis, clinical features, presentation

Treatment of endometrial cancer with a focus on advanced and recurrent disease

  • Brief review of early disease stage treatment approaches: surgical therapy, radiotherapy, cytotoxic chemotherapy, brachytherapy, hormonal therapy
  • Isolated vaginal recurrence
  • Recurrence limited to the pelvis
  • Radiation history
  • Metastic disease
  • 1st-line, 2nd-line
  • ±Mismatch repair-deficient or microsatellite -instable tumors
  • Role of biomarkers
  • Newly approved therapy
  • Investigational therapy
  • Other gaps in care (e.g., Lynch syndrome)
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap


Learning Objectives

By the end of the session the participant will be able to:

  • Review guideline-recommended therapy for advanced and recurrent endometrial cancer.
  • Distinguish between the different forms of therapy presently approved for advanced or recurrent endometrial cancer and apply them to practice.
  • Describe investigational therapies for advanced or recurrent endometrial cancer and their anticipated place in therapy.
  • Describe the challenges and barriers to care associated with treating patients with advanced or recurrent endometrial cancer.


ACCME Activity #0


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Daphne B. Stewart, MD, MS, Associate Clinical Professor, City of Hope National Medical Center, has no relevant financial discloses.

Disclosures of Educational Planners: Charles Turck, PharmD, has no relevant financial discloses.

Commercial Support Disclosure: This program is supported by educational grants from Karyopharm


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Advances in Treating Triple-Negative Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies

Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments

Advanced prostate cancer: Optimizing management strategies

Treating Oncology Patients During COVID-19